The Quantellect read.As of Nov 19, 2026, 18 active firms cover GE HealthCare Technologies Inc: 10 rate it Buy or better, 8 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $14.00 to $105.00 (about 7.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $78.78 sits 5% below the current $82.78. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 8 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.11 next quarter toward $5.50 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS18 active firms
Buy
Strong Buy00%
Buy1056%
Neutral844%
Sell00%
Strong Sell00%
Based on 18 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$78.78
-4.8% downside
Average target across 18 active firms as of Nov 19, 2026 vs $82.78 current
Highest Target$105.00
Average Target$78.78
Lowest Target$14.00
Detailed analyst forecasts for GEHC
Showing 1–17 of 17 named analysts shown · 18 active firms in the rating projection
As of Nov 19, 2026, 10 of 18 active firms rate GEHC a Buy (8 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
GEHC EPS & revenue forecast
EPS · NEXT QUARTER
$1.11
Range $0.99 – $1.25 · 12 analysts · +12% YoY
Next period, 12 analysts expect GE HealthCare Technologies Inc. to earn $1.11 a share (range $0.99 – $1.25), versus $0.99 a year earlier. Full-year consensus is $5.02, growing to $5.50 the year after.
REVENUE · NEXT QUARTER
$5.4B
Range $5.3B – $5.4B · 12 analysts · +5% YoY
Revenue is expected to reach $5.4B (range $5.3B – $5.4B), +4.6% year-over-year. Full-year consensus is $21.9B, rising to $22.9B next year.
Top analysts covering GE HealthCare Technologies Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GEHC.
#1
Joanne Wuensch
Citigroup · Rank #35
Neutral
$79.00-4.6% to target
Overall win rate
51%
+ Follow
#2
Anthony Petrone
Mizuho · Rank #121
Buy
$85.00+2.7% to target
Overall win rate
45%
+ Follow
#3
Ryan Zimmerman
BTIG · Rank #212
Buy
$75.00-9.4% to target
Overall win rate
37%
+ Follow
#4
Vijay Kumar
Evercore ISI Group · Rank #331
Buy
$84.00+1.5% to target
Overall win rate
36%
+ Follow
#5
Jason Bednar
Piper Sandler · Rank #360
Buy
$74.00-10.6% to target
Overall win rate
33%
+ Follow
GEHC stock forecast FAQ
What is GEHC's average 12-month price target?+
The 18 active firms with a live target average $78.78 for GE HealthCare Technologies Inc. over the next 12 months, ranging from a $105.00 high to a $14.00 low, as of Nov 19, 2026.
Is GEHC stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 18 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 8 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for GEHC?+
The Street-high target is $105.00 (Jefferies), and the Street-low is $14.00. The average of all 18 active-firm targets is $78.78.
How many active Wall Street firms cover GEHC?+
18 active firms have a recognized rating on GE HealthCare Technologies Inc. as of Nov 19, 2026, and 18 active firms carry a live 12-month price target.
Who is the most accurate analyst covering GEHC?+
Among analysts who currently cover GEHC, Joanne Wuensch of Citigroup has the strongest overall Quantellect track record (Rank #35). Their current call is Neutral with a $79.00 target.
What is GE HealthCare Technologies Inc.'s projected EPS for next quarter?+
The consensus estimate is $1.11 per share (range $0.99 – $1.25) across 12 analysts. Full-year EPS is projected at $5.02, rising to $5.50 the following year.
How much revenue is GE HealthCare Technologies Inc. expected to report next quarter?+
Consensus revenue is $5.4B (range $5.3B – $5.4B). Full-year revenue is projected at $21.9B, growing to $22.9B next year.
Have analysts been upgrading or downgrading GEHC lately?+
As of Nov 19, 2026, 10 of 18 active firms rate GEHC a Buy (8 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GEHC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.